ACE2 News and Research

RSS

Two potent SARS-CoV-2 neutralizing antibodies effective against B.1.351 and B.1.1.7 variants

By analyzing the cryoEM structures of antibodies against the SARS-CoV-2 virus, researchers report that the neutralizing capabilities of two antibodies are not affected by new strains as these antibodies target regions of the virus away from the ACE2 binding regions.

23 Feb 2021

Research predicts which mammal species can spread SARS-CoV-2

Scientists worldwide are fighting to contain the ongoing COVID-19 pandemic, which has already claimed more than 2.48 million lives. Preventing spillback infections is essential to containing the pandemic. To do so, it is vital to understand the nature of the virus, i.e., its susceptibility to a range of hosts.

23 Feb 2021

Key mutation sites in the SARS-CoV-2 spike protein modulate antibody and ACE2 affinity

A paper recently uploaded to the preprint server bioRxiv by researchers at Chapman University in California (Feb 22nd, 2021) utilized computational methods to screen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutants for affinity with the angiotensin-converting enzyme 2 (ACE2) receptor and monoclonal antibodies REG10987 and REG10933.

23 Feb 2021

SARS-CoV-2 mutations allow escape from clinical monoclonal antibodies

A new research paper recently uploaded to the preprint server bioRxiv by Jesse D. Bloom et al. (22nd Feb 2021) aims to map all of the currently circulating SARS-CoV-2 lineages with resistance towards LY-CoV555 and LY-CoV016, and document the specific mutations that confer resistance, ultimately suggesting that future monoclonal antibody cocktails should target a more diverse range of epitopes.

23 Feb 2021

Could laser-facilitated epicutaneous vaccination for SARS-CoV-2 be an alternative to intramuscular injection?

Scientists at the University of Salzburg and Pantec Biosolutions AG have developed a laser-facilitated epicutaneous immunization against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. The model has induced angiotensin-converting enzyme 2 (ACE2) blocking antibodies in mice.

23 Feb 2021

How effective has Israel’s SARS-CoV-2 testing and vaccination campaign been against the UK variant?

A recent study by researchers at Tel Aviv University describes the UK variant’s rise to dominance in Israel. It also assesses the efficacy of the testing and vaccination programs employed by the government.

23 Feb 2021

L452R mutation potentially favors adaptive evolution of SARS-CoV-2

A team of scientists from the United States recently investigated the mutational signatures in the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein.

23 Feb 2021

Could rotavirus vaccine platforms aid in the immunization campaign against SARS-CoV-2?

The study began with the generation of recombinant (r)SA11 rotaviruses, into which segment 7 modified RNAs were introduced. These encoded sequences for the non-structural protein NSP3 and some parts of the viral spike.

23 Feb 2021

Cannabinoid receptor agonist shows potential protective effect on SARS-CoV-2-infected human heart cells

As scientists continue to search for effective antidotes to direct and indirect damage caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new preprint research paper posted to the bioRxiv* server demonstrates the potential of cannabinoid receptor agonists to alleviate myocardial damage in this condition even in the absence of any inhibitory effect on viral infection as such.

23 Feb 2021

Fooling the novel coronavirus with a fake handshake to inactivate the virus

Fool the novel coronavirus once and it can't cause infection of cells, new research suggests.

22 Feb 2021

WVU researchers set to identify SARS-CoV-2 variants, mitigate strain outbreaks

West Virginia University scientists knew it was coming. When health officials confirmed the first three cases of a COVID-19 variant in West Virginia late Friday (Feb. 19), they were not surprised.

22 Feb 2021

No evidence of SARS-CoV-2 fusing into the human genome

New data from researchers led by Majid Kazemian from Purdue University refutes claims from recent studies suggesting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could create a host-virus chimeric RNA. Their team found SARS-CoV-2 does not combine with the human genome.

22 Feb 2021

Researchers uncover 'hotspots' on the Spike protein that are critical for SARS-CoV-2 infection

The COVID-19 pandemic has prompted considerable investigation into how the SARS-CoV-2 Spike protein attaches to a human cell during the infection process, as this knowledge is useful in designing vaccines and therapeutics.

22 Feb 2021

An overview of spike protein antigen COVID-19 vaccine candidates

A new paper in the journal Reviews in Medical Virology provides a perspective on current vaccine development strategies and tools, which may allow the production of safe and effective vaccines.

22 Feb 2021

COVID-19 vaccine candidate shows potential against SARS-CoV-2 and potential future zoonotic coronaviruses

A new study sheds light on the threat posed by future zoonotic coronaviruses to make similar leaps across species barriers to infect human beings and cause other pandemics.

22 Feb 2021

Some nutritional supplements may help prevent or mitigate COVID-19 severity

A new study in the Journal of dietary supplements shows that nutritional supplements, including several vitamins and the mineral zinc, may be useful in preventing the infection or reducing its severity if caught.

22 Feb 2021

Polyphenols may provide protective effect against COVID-19 disease

In the study published in the journal Integrative Physiology, the researchers found that a high intake of polyphenols may have a protective effect on patients with COVID-19 and prevent disease progression.

22 Feb 2021

Mucosal delivery of IFNs a good strategy for COVID-19 prophylaxis post-exposure

Researchers from the UK and Germany recently reported a comprehensive characterization of the SARS-CoV-2 response of human nasal epithelial cells, revealing a response dominated by IFN-I/IIIs. Also, recombinant IFN-I/III treatment was found to efficiently block the replication of SARS-CoV-2, which suggests that mucosal delivery of IFNs may be a good strategy for prophylaxis post-exposure.

22 Feb 2021

Gold nanoparticles investigated as part of in vitro tool for SARS-CoV-2 drug screening

Scientists have measured the interaction of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein with nano-gold colloids. These nanoparticles functionalized with the S protein have different spectroscopic signals allowing for new information about the protein to be extracted.

21 Feb 2021

Proteases modulate SARS-CoV-2 spike protein activation and deactivation

A research paper recently uploaded to the preprint server bioRxiv by Platt et al. (17th Feb 2021) aimed to identify these enzymes by computational screening and molecular docking simulations, with cathepsins B, K, L, S, and V being highlighted as probable leads.

21 Feb 2021

ACE2 News and Research

Two potent SARS-CoV-2 neutralizing antibodies effective against B.1.351 and B.1.1.7 variants

Research predicts which mammal species can spread SARS-CoV-2

Key mutation sites in the SARS-CoV-2 spike protein modulate antibody and ACE2 affinity

SARS-CoV-2 mutations allow escape from clinical monoclonal antibodies

Could laser-facilitated epicutaneous vaccination for SARS-CoV-2 be an alternative to intramuscular injection?

How effective has Israel’s SARS-CoV-2 testing and vaccination campaign been against the UK variant?

L452R mutation potentially favors adaptive evolution of SARS-CoV-2

Could rotavirus vaccine platforms aid in the immunization campaign against SARS-CoV-2?

Cannabinoid receptor agonist shows potential protective effect on SARS-CoV-2-infected human heart cells

Fooling the novel coronavirus with a fake handshake to inactivate the virus

WVU researchers set to identify SARS-CoV-2 variants, mitigate strain outbreaks

No evidence of SARS-CoV-2 fusing into the human genome

Researchers uncover 'hotspots' on the Spike protein that are critical for SARS-CoV-2 infection

An overview of spike protein antigen COVID-19 vaccine candidates

COVID-19 vaccine candidate shows potential against SARS-CoV-2 and potential future zoonotic coronaviruses

Some nutritional supplements may help prevent or mitigate COVID-19 severity

Polyphenols may provide protective effect against COVID-19 disease

Mucosal delivery of IFNs a good strategy for COVID-19 prophylaxis post-exposure

Gold nanoparticles investigated as part of in vitro tool for SARS-CoV-2 drug screening

Proteases modulate SARS-CoV-2 spike protein activation and deactivation

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News